Classifying PE Severity Before Choosing Therapy
Severity class sets the whole treatment path forward.
- ~60%: Low-risk PE share (placeholder stat)
- ~35%: Submassive PE share (placeholder stat)
- ~5%: Massive PE share (placeholder stat)
- ~30%: Massive PE mortality (placeholder stat)
How severity is determined
Placeholder: imaging, biomarkers, and vitals set risk class.
Why classification comes first
Placeholder: treatment intensity must match clot burden and instability.
Heparin Bridge to DOAC for Stable PE
Most patients start anticoagulation, not clot-dissolving drugs.
- Heparin: First-line agent (placeholder stat)
- ~5 days: Bridge duration (placeholder stat)
- ~2%: Major bleeding risk (placeholder stat)
- DOAC: Long-term agent (placeholder stat)
Why anticoagulation is default
Placeholder: favorable risk-benefit for stable, non-massive PE.
Heparin-to-DOAC transition
Placeholder: overlap dosing until DOAC reaches steady state.
How Anticoagulation Clears Clot Without Dissolving It Directly
The body's own fibrinolysis does the dissolving, slowly.
- ~1–2 wks: Clot half-clearance (placeholder stat)
- Blocked: New clot growth (placeholder stat)
- Weeks–months: Full resolution (placeholder stat)
- ~90%: Recurrence reduction (placeholder stat)
Preventing propagation
Placeholder: anticoagulants stop the clot from growing further.
Natural fibrinolysis at work
Placeholder: endogenous plasmin gradually breaks down existing clot.
Thrombolysis for Hemodynamically Unstable PE
Rapid clot dissolution is weighed against major bleeding risk.
- Hours: Clot dissolution time (placeholder stat)
- ~10–12%: Major bleeding risk (placeholder stat)
- ~2–3%: Intracranial hemorrhage (placeholder stat)
- Alteplase: Agent (placeholder stat)
When thrombolysis is considered
Placeholder: reserved for shock or hemodynamic collapse.
The bleeding tradeoff
Placeholder: rapid benefit weighed against hemorrhage risk.
Matching Treatment Intensity to Severity
Anticoagulation for most; thrombolysis only when life-threatening.
- ~95%: Anticoagulation-treated (placeholder stat)
- ~5%: Thrombolysis-treated (placeholder stat)
- Avoidable: Mismatch bleeding risk (placeholder stat)
- Avoidable: Mismatch undertreatment risk (placeholder stat)
Why matching matters
Placeholder: mismatched therapy raises harm without added benefit.
Placeholder: severity-matched therapy optimizes risk-benefit outcomes.